Tyrosine kinase inhibitorFDA-approvedFirst-line
Xalkori
Generic name: crizotinib
How it works
Blocks the activity of the anaplastic lymphoma kinase (ALK) and the MET receptors, which are involved in the growth and spread of cancer cells.
Cancer types
Lung Cancer— ALK-positive
Efficacy
In clinical trials, patients with ALK-positive lung cancer treated with crizotinib had a median progression-free survival of approximately 10.9 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Crizotinib and Next-Generation Treatments for Lung Cancer | Lung Cancer | observational | Crizotinib achieved an overall response rate of 78.5% and a median progression-free survival of 22.4 months. | Source → |
| New Cancer Treatment Approach Uses Light to Target Tumors | Lung Cancer | lab-study | — | Source → |
| Long-term benefits of lorlatinib for lung cancer patients | Lung Cancer | phase-3 | 7-year PFS was 55% with lorlatinib and 3% with crizotinib. | Source → |
| Inflammation markers linked to lung cancer treatment outcomes | Lung Cancer | phase-2 | The overall response rate was 77.2%, while 1-year OS and PFS rates were 95.0% and 93.5%, respectively. | Source → |
| ALK-positive Lung Cancer Patients Respond to Crizotinib in Spain | Lung Cancer | observational | The overall response rate was 59.3% and the median progression-free survival was 15.8 months. | Source → |
| Teenager with Lung Cancer Responds Well to Crizotinib | Lung Cancer | observational | He obtained a prolonged response with PFS of 33 months. | Source → |
| Crizotinib's Effectiveness in ROS1-Positive Lung Cancer Patients | Lung Cancer | observational | The median overall survival was 36.2 months. | Source → |
| Long-term Survival Benefits of Sequential Cancer Treatment in China | Lung Cancer | observational | Estimated 5-year OS was 68.6% in the overall population. | Source → |
| Cost-effectiveness of crizotinib in treating lung cancer | Lung Cancer | phase-3 | Crizotinib produced additional 0.885 life-years and 0.772 quality-adjusted life-years (QALYs) at an incremental cost of $238,077, producing an ICER of $273,286/QALY gained. | Source → |
| Rare Lung Cancer Gene Responds to Treatment | Lung Cancer | observational | After 3 weeks of treatment, the patient had a partial response. | Source → |
| Crizotinib and Cabozantinib Treatments Help Patient with Rare Lung Cancer Mutation | Lung Cancer | observational | The patient's disease achieved partial regression and progression-free survival lasted for 8 months, and overall survival was >12 months. | Source → |
| Resistance to Cancer Drug Crizotinib Found in Lung Cancer Patients | Lung Cancer | lab-study | — | Source → |
| Targeted Therapy for Lung Cancer: A Case Study | Lung Cancer | observational | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.